Yet SOX2 amplification and subsequent overexpression have also been shown in a variety of malignancies, including breast cancer, gastric cancer, and prostate cancer [32], raising the possibility that SOX2 is an oncogene. This evidence concerns the gene SOX2 and breast carcinoma.